ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Leucovorin: Drug information

Leucovorin: Drug information
2024© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Leucovorin: Patient drug information" and "Leucovorin: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: Canada
  • Lederle Leucovorin;
  • MINT-Leucovorin;
  • RIVA Leucovorin
Pharmacologic Category
  • Antidote;
  • Chemotherapy Modulating Agent;
  • Rescue Agent (Chemotherapy);
  • Vitamin, Water Soluble
Dosing: Adult

Dosage guidance:

Safety: Leucovorin may be harmful or fatal if given intrathecally (Ref). Do not administer leucovorin intrathecally; the use of intrathecal leucovorin is not advised (Ref).

Dosing: Because oral absorption is saturable at doses >25 mg, administering single oral doses >25 mg is not recommended (convert to parenteral therapy).

Clinical considerations : Please refer to the protocol or institutional guidance for additional details on off-label dosing. Leucovorin calcium is a substrate for glucarpidase and may compete with methotrexate for binding sites; when administering glucarpidase concomitantly with leucovorin calcium, administer leucovorin calcium ≥2 hours before or 2 hours after the glucarpidase dose (Ref).

Acute lymphocytic leukemia

Acute lymphocytic leukemia (off-label use):

Hyper-CVAD alternating with high-dose methotrexate/cytarabine regimen: IV: 50 mg administered 12 hours after methotrexate completion, followed by 15 mg every 6 hours for 8 doses or until methotrexate level is <0.1 micromolar (adjust dose based on methotrexate level as needed) (Ref) or 15 mg administered 12 hours after methotrexate completion, followed by 15 mg every 6 hours for 8 total doses or until methotrexate level is <0.1 micromolar (adjust dose based on methotrexate level as needed) (Ref). Therapy consists of alternating cycles of hyper-CVAD (cyclophosphamide, mesna, vincristine, doxorubicin, and dexamethasone) and high-dose methotrexate/cytarabine.

Linker regimen: IV: 15 mg/m2 every 6 hours for 12 doses starting at the end of methotrexate infusion during the ninth consolidation course (Ref) or 50 mg/m2 every 6 hours for 3 doses during consolidation courses 1C, 2C, and 3C; then transition to oral leucovorin after the third IV dose and continue until methotrexate level is <0.05 micromolar (Ref).

Anal carcinoma, advanced

Anal carcinoma, advanced (off-label use): FOLFCIS regimen: IV: 400 mg/m2 once every 2 weeks (in combination with fluorouracil and cisplatin); continue until disease progression or unacceptable toxicity (Ref).

Biliary tract cancer, metastatic, progressive

Biliary tract cancer, metastatic, progressive (off-label use): IV: 400 mg/m2 over 30 minutes once every 2 weeks (in combination with fluorouracil and irinotecan [liposomal]); continue until disease progression or unacceptable toxicity (Ref).

Bladder cancer, neoadjuvant treatment

Bladder cancer, neoadjuvant treatment (off-label use): CMV regimen: IV, Oral: 15 mg every 6 hours for 4 doses on days 2 and 9, starting 24 hours after each methotrexate dose (in combination with methotrexate, vinblastine, and cisplatin) (Ref).

Colorectal cancer, advanced

Colorectal cancer, advanced: IV: 200 mg/m2/day over ≥3 minutes for 5 days every 4 weeks for 2 cycles, then every 4 to 5 weeks (in combination with fluorouracil) or 20 mg/m2/day for 5 days every 4 weeks for 2 cycles, then every 4 to 5 weeks (in combination with fluorouracil). Note: Multiple leucovorin-containing regimens are available for the treatment of colorectal cancer; may be in combination with other agents (eg, monoclonal antibodies). Refer to appropriate literature/guidelines for additional details.

Roswell Park regimen (off-label dosing): IV: 500 mg/m2 over 2 hours on days 1, 8, 15, 22, 29, and 36 (in combination with fluorouracil, administered 1 hour after the start of leucovorin) every 8 weeks for 4 cycles (Ref).

FOLFOX6 and mFOLFOX6 regimen (off-label dosing): IV: 400 mg/m2 over 2 hours on day 1 or 350 mg (flat dose) over 2 hours on day 1 (in combination with fluorouracil and oxaliplatin) every 2 weeks until disease progression or unacceptable toxicity (Ref).

mFOLFOX7 regimen (off-label dosing): IV: 200 mg/m2 over 2 hours once every 2 weeks (in combination with fluorouracil and oxaliplatin) until disease progression or unacceptable toxicity (Ref).

FOLFIRI regimen (off-label dosing): IV: 400 mg/m2 over 2 hours on day 1 every 2 weeks (in combination with fluorouracil and irinotecan) until disease progression or unacceptable toxicity (Ref).

Dermatomyositis/polymyositis

Dermatomyositis/polymyositis (off-label use): Oral: 5 mg once per week (administered 8 to 12 hours after the methotrexate dose) (Ref).

Esophageal cancer, advanced or metastatic

Esophageal cancer, advanced or metastatic (off-label use):

FOLFIRI regimen: IV: 400 mg/m2 over 2 hours once every 2 weeks (in combination with fluorouracil and irinotecan) until disease progression or unacceptable toxicity (Ref).

FLO regimen (locally advanced, recurrent, or metastatic disease): IV: 200 mg/m2 over 2 hours once every 2 weeks (in combination with fluorouracil and oxaliplatin) until disease progression or unacceptable toxicity (Ref).

FLOT regimen (locally advanced, resectable gastroesophageal junction adenocarcinoma): IV: 200 mg/m2 on day 1 every 2 weeks (in combination with fluorouracil, oxaliplatin, and docetaxel) for 4 preoperative cycles and 4 postoperative cycles (Ref).

FOLFOX/nivolumab: IV: 400 mg/m2 on day 1 every 2 weeks (in combination with fluorouracil, oxaliplatin, and nivolumab) until disease progression or unacceptable toxicity (Ref).

FOLFOX4 regimen (chemoradiotherapy for locally advanced, recurrent, or metastatic disease): IV: 200 mg/m2 over 2 hours on day 1 every 2 weeks, in combination with fluorouracil and oxaliplatin and radiation for 3 cycles, then without radiation for 3 more cycles (Ref).

mFOLFOX6 (metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or gastroesophageal junction): IV: 400 mg/m2 over 2 hours on day 1 every 2 weeks (in combination with fluorouracil and oxaliplatin) until disease progression or unacceptable toxicity (Ref).

mDCF regimen (advanced gastroesophageal junction adenocarcinoma): IV: 400 mg/m2 over 30 minutes on day 1 every 2 weeks (in combination with docetaxel, fluorouracil, and cisplatin) until disease progression or unacceptable toxicity (Ref).

Folic acid antagonist overdose

Folic acid antagonist (eg, trimethoprim, pyrimethamine) overdose: Oral: 5 to 15 mg once daily.

Gastric cancer, advanced or metastatic

Gastric cancer, advanced or metastatic (off-label use):

FOLFIRI regimen: IV: 400 mg/m2 over 2 hours once every 2 weeks (in combination with fluorouracil and irinotecan) until disease progression or unacceptable toxicity (Ref).

FLO regimen: IV: 200 mg/m2 over 2 hours once every 2 weeks (in combination with fluorouracil and oxaliplatin) until disease progression or unacceptable toxicity (Ref).

FLOT regimen: IV: 200 mg/m2 on day 1 every 2 weeks (in combination with fluorouracil, oxaliplatin, and docetaxel) for 4 preoperative cycles and 4 postoperative cycles (Ref).

FOLFOX/nivolumab: IV: 400 mg/m2 on day 1 every 2 weeks (in combination with fluorouracil, oxaliplatin, and nivolumab) until disease progression or unacceptable toxicity (Ref).

mDCF regimen (advanced gastric adenocarcinoma): IV: 400 mg/m2 over 30 minutes on day 1 every 2 weeks (in combination with docetaxel, fluorouracil, and cisplatin) until disease progression or unacceptable toxicity (Ref).

Gestational trophoblastic neoplasia

Gestational trophoblastic neoplasia (off-label use):

Low-risk disease: 8-day regimen: Oral: 30 mg every 48 hours (on days 2, 4, 6, and 8) for 4 doses (30 hours after each methotrexate dose), repeat cycle every 14 days until hCG level is normal, followed by 2 to 3 more cycles as consolidation therapy (Ref).

High-risk metastatic disease: Note: The oral route would be preferred over IM in patients with thrombocytopenia.

EMA-CO regimen: Oral, IM: 15 mg every 12 hours for 4 doses, beginning 24 hours after the start of methotrexate (in combination with etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine); patients with brain metastases received a higher methotrexate dose and, therefore, the leucovorin calcium dose was increased to 30 mg every 12 hours for 6 doses, beginning 32 hours after the start of methotrexate. Continue for ≥2 treatment cycles after a normal human chorionic gonadotropin (hCG) level (Ref).

EMA-EP regimen: Oral, IM: 15 mg every 12 hours for 4 doses beginning on day 2 (in combination with etoposide, methotrexate, dactinomycin, and cisplatin); patients with brain metastases received a higher methotrexate dose and, therefore, an increased leucovorin calcium dose of 30 mg every 12 hours. Continue for 2 to 4 treatment cycles after a normal hCG level (Ref).

EP-EMA regimen: Oral, IM: 15 mg every 12 hours for 4 doses, beginning 24 hours after the start of methotrexate (in combination with etoposide, cisplatin, methotrexate, and dactinomycin); if mucositis develops, may double the dose and duration of leucovorin calcium (Ref).

Graft-versus-host disease, acute, prophylaxis

Graft-versus-host disease, acute, prophylaxis (off-label use): IV: 15 mg every 6 hours for 3 doses on day 2, then 15 mg every 6 hours for 4 doses on days 4, 7, and 12; initiate leucovorin 24 hours after each methotrexate dose (methotrexate is administered on days 1, 3, 6, and 11; may omit day 11 methotrexate for ≥ grade 2 toxicity) (Ref).

Granulomatosis with polyangiitis and microscopic polyangiitis

Granulomatosis with polyangiitis and microscopic polyangiitis (maintenance therapy after remission induction) (off-label use): Oral: 5 to 10 mg once weekly administered 24 hours after methotrexate (Ref) or 25 mg once weekly administered 48 hours after methotrexate (Ref).

Hepatobiliary cancers, advanced

Hepatobiliary cancers, advanced (off-label use): IV: 25 mg/m2 immediately prior to fluorouracil infusion on days 1, 8, and 15 every 4 weeks (in combination with gemcitabine and fluorouracil) (Ref).

Megaloblastic anemia, folate-deficient

Megaloblastic anemia, folate-deficient: IM, IV: ≤1 mg once daily.

Methanol toxicity, adjunctive cofactor therapy

Methanol toxicity, adjunctive cofactor therapy (off-label use): IV: 1 mg/kg (maximum dose: 50 mg) over 30 to 60 minutes every 4 to 6 hours. Therapy should continue until methanol and formic acid have been completely eliminated (Ref).

Methotrexate-rescue, for high-dose methotrexate

Methotrexate-rescue, for high-dose methotrexate: Initial: Oral, IV: 15 mg (~10 mg/m2); start 24 hours after beginning methotrexate infusion; continue every 6 hours for ~10 doses (duration based on methotrexate level), until methotrexate level is <0.05 micromolar. Monitor hydration and electrolyte status, as well as urine alkalinization. Adjust dose per institutional protocol or as follows:

Normal methotrexate elimination (serum methotrexate level ~10 micromolar at 24 hours after administration, 1 micromolar at 48 hours, and <0.2 micromolar at 72 hours): Oral, IV: 15 mg every 6 hours for 60 hours (10 doses) beginning 24 hours after the start of methotrexate infusion.

Delayed late methotrexate elimination (serum methotrexate level remaining >0.2 micromolar at 72 hours and >0.05 micromolar at 96 hours after administration): Continue leucovorin calcium 15 mg (oral or IV) every 6 hours until methotrexate level is <0.05 micromolar.

Delayed early methotrexate elimination and/or acute renal injury (serum methotrexate level ≥50 micromolar at 24 hours, or ≥5 micromolar at 48 hours, or a doubling of serum creatinine level at 24 hours after methotrexate administration): IV: 150 mg every 3 hours until methotrexate level is <1 micromolar, then 15 mg every 3 hours until methotrexate level is <0.05 micromolar.

Methotrexate overdose, inadvertent

Methotrexate overdose, inadvertent: Note: Begin as soon as possible after overdose. Oral, IV: 10 mg/m2 every 6 hours until the methotrexate level is <0.01 micromolar. If serum creatinine is increased >50% above baseline 24 hours after methotrexate administration, if 24 hour methotrexate level is >5 micromolar, or if 48 hour methotrexate level is >0.9 micromolar, increase leucovorin dose to 100 mg/m2 IV every 3 hours until the methotrexate level is <0.01 micromolar.

Methotrexate overexposure, high-dose methotrexate

Methotrexate overexposure, high-dose methotrexate (off-label dosing): Leucovorin nomogram dosing for high-dose methotrexate overexposure; generalized dosing derived from reference nomogram figures, refer to each reference (Ref) or institution-specific nomogram for details:

At 24 hours:

For methotrexate levels of ≥100 micromolar at ~24 hours, leucovorin calcium is initially dosed at 1,000 mg/m2 IV every 6 hours.

For methotrexate levels of ≥10 to <100 micromolar at 24 hours, leucovorin calcium is initially dosed at 100 mg/m2 IV every 3 or 6 hours.

For methotrexate levels of ~1 to 10 micromolar at 24 hours, leucovorin calcium is initially dosed at 10 mg/m2 IV or orally every 3 or 6 hours.

At 48 hours:

For methotrexate levels of ≥100 micromolar at 48 hours, leucovorin calcium is dosed at 1,000 mg/m2 IV every 6 hours.

For methotrexate levels of ≥10 to <100 micromolar at 48 hours, leucovorin calcium is dosed at 100 mg/m2 IV every 3 hours.

For methotrexate levels of ~1 to 10 micromolar at 48 hours, leucovorin calcium is dosed at 100 mg/m2 IV every 6 hours or 10 mg/m2 IV or orally to 100 mg/m2 IV every 3 hours.

At 72 hours:

For methotrexate levels of ≥10 micromolar at 72 hours, leucovorin calcium is dosed at 100 to 1,000 mg/m2 IV every 3 to 6 hours.

For methotrexate levels of ~1 to 10 micromolar at 72 hours, leucovorin calcium is dosed at 10 mg/m2 IV or orally to 100 mg/m2 IV every 3 hours.

For methotrexate levels of ~0.1 to 1 micromolar at 72 hours, leucovorin calcium is dosed at 10 mg/m2 IV or orally every 3 to 6 hours.

If serum creatinine is increased >50% above baseline, increase the standard leucovorin calcium dose to 100 mg/m2 IV every 3 hours, then adjust according to methotrexate levels above.

Follow methotrexate levels daily, leucovorin calcium may be discontinued when methotrexate level is <0.1 micromolar.

Some regimens use the following equation when calculating the leucovorin calcium dose (if the methotrexate plasma concentration is >5 micromolar) (Ref):

Plasma methotrexate concentration (micromolar) × body weight (kg)

Non-Hodgkin lymphoma, Burkitt or high-grade

Non-Hodgkin lymphoma, Burkitt or high-grade (off-label use):

CODOX-M/IVAC regimen: IV, Oral: 15 mg/m2 IV every 3 hours for 5 doses beginning at hour 36 after the start of methotrexate, then 15 mg/m2 IV every 6 hours until methotrexate level is <0.05 micromolar. In addition, leucovorin calcium 15 mg (flat dose) orally is administered 24 hours after intrathecal methotrexate (Ref) or 200 mg/m2 IV as a one-time dose 24 hours after the start of methotrexate, followed by 15 mg/m2 IV every 6 hours until methotrexate level is <0.1 micromolar (Ref). CODOX-M cycle (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate with leucovorin calcium rescue, intrathecal cytarabine, and intrathecal methotrexate) alternates with IVAC cycle (etoposide, ifosfamide, mesna, cytarabine, and intrathecal methotrexate (with leucovorin calcium rescue).

Hyper-CVAD alternating with high-dose methotrexate/cytarabine regimen: IV, Oral: 50 mg IV administered 12 hours after methotrexate completion, followed by 15 mg IV every 6 hours for 8 doses or until methotrexate level is <0.1 micromolar (adjust dose based on methotrexate level as needed) (Ref) or 50 mg IV administered 24 hours after the end of methotrexate infusion, followed by 15 mg orally every 6 hours for 8 doses (adjust dose based on methotrexate level as needed) (Ref). Therapy consists of alternating cycles of hyper-CVAD (cyclophosphamide, mesna, vincristine, doxorubicin, and dexamethasone) and high-dose methotrexate/cytarabine.

Nonleukemic meningeal cancer

Nonleukemic meningeal cancer (off-label use): Oral: 10 mg every 6 hours for 8 doses, beginning 24 hours after each intrathecal methotrexate dose (Ref).

Pancreatic cancer, advanced or metastatic

Pancreatic cancer, advanced or metastatic (off-label use):

Fluorouracil with irinotecan (liposomal): IV: 400 mg/m2 over 30 minutes once every 2 weeks (in combination with fluorouracil and irinotecan [liposomal]); continue until disease progression or unacceptable toxicity (Ref).

FOLFIRINOX regimen: IV: 400 mg/m2 over 2 hours once every 2 weeks (in combination with fluorouracil, oxaliplatin, and irinotecan) for ≥6 months (Ref).

NALIRIFOX regimen (first-line therapy): IV: 400 mg/m2 over 30 minutes once every 2 weeks (in combination with fluorouracil, oxaliplatin, and irinotecan [liposomal]); continue until disease progression or unacceptable toxicity (Ref).

OFF regimen (second-line therapy): IV: 200 mg/m2 on days 1, 8, 15, and 22 every 6 weeks (in combination with fluorouracil and oxaliplatin) until disease progression or unacceptable toxicity (Ref).

Pancreatic cancer, potentially curable, adjuvant therapy

Pancreatic cancer, potentially curable, adjuvant therapy (off-label use): Note: American Society of Clinical Oncology (ASCO) guidelines recommend 6 months of adjuvant therapy if recovery is complete; if preoperative chemotherapy therapy was received, a total of 6 months of adjuvant therapy (including the preoperative regimen) is recommended (Ref).

mFOLFIRINOX regimen: IV: 400 mg/m2 over 2 hours once every 2 weeks (in combination with fluorouracil, irinotecan, and oxaliplatin; modified FOLFIRINOX [mFOLFIRINOX] regimen) for 24 weeks (Ref). According to ASCO guidelines, mFOLFIRINOX is the preferred first-line adjuvant regimen for potentially curable disease (Ref).

Prevention of pyrimethamine hematologic toxicity in patients with HIV

Prevention of pyrimethamine hematologic toxicity in patients with HIV (off-label use) (Ref):

Cystoisosporiasis (formerly Isosporiasis):

Treatment: Oral: 10 to 25 mg once daily (in combination with pyrimethamine).

Chronic maintenance (secondary prophylaxis): Oral: 5 to 10 mg once daily (in combination with pyrimethamine).

Pneumocystis pneumonia: Prophylaxis (primary and secondary): Oral: 25 mg once weekly (in combination with pyrimethamine and dapsone) or 10 mg once daily (in combination with pyrimethamine and atovaquone).

Toxoplasma gondii encephalitis:

Primary prophylaxis: Oral: 25 mg once weekly (in combination with pyrimethamine and dapsone) or 10 mg once daily (in combination with pyrimethamine and atovaquone).

Treatment: Oral: 10 to 25 mg once daily as part of an appropriate combination regimen. Note: May increase leucovorin to 50 mg once or twice daily in cases of pyrimethamine toxicity (rash, nausea, bone marrow suppression).

Chronic maintenance (secondary prophylaxis): Oral: 10 to 25 mg once daily (in combination with pyrimethamine with either sulfadiazine or clindamycin) or 10 mg once daily (in combination with pyrimethamine and atovaquone).

Primary CNS lymphoma, newly diagnosed

Primary CNS lymphoma, newly diagnosed (off-label use): IV, Oral: 20 to 25 mg every 6 hours beginning 24 hours after methotrexate infusion (in combination with rituximab, methotrexate, vincristine, and procarbazine, followed by radiotherapy, cytarabine, and intra-Ommaya methotrexate), continue for ≥72 hours or until methotrexate level is <0.1 micromolar; may increase dose to 40 mg every 4 hours for elevated methotrexate levels (Ref) or 100 mg/m2 IV every 6 hours starting 24 hours after methotrexate infusion, continue until methotrexate level is <0.05 micromolar (in combination with methotrexate, temozolomide, and rituximab, followed by high-dose consolidation therapy) (Ref) or 25 mg IV every 6 hours starting 24 hours after methotrexate, continue until appropriate methotrexate level is reached (in combination with methotrexate, temozolomide, and rituximab, followed by whole brain radiotherapy) (Ref).

Small bowel adenocarcinoma, advanced or metastatic

Small bowel adenocarcinoma, advanced or metastatic (off-label use): Note: Ampullary adenocarcinomas were excluded from these studies (Ref).

FOLFIRI regimen (following progression on a platinum-based regimen): IV: 400 mg/m2 over 2 hours on day 1 every 2 weeks (in combination with fluorouracil and irinotecan) until disease progression or unacceptable toxicity (Ref).

mFOLFOX or FOLFOX regimen: IV: 400 mg/m2 over 2 hours on day 1 every 2 weeks (in combination with fluorouracil and oxaliplatin) until disease progression or unacceptable toxicity (Ref).

Tubal ectopic pregnancy

Tubal ectopic pregnancy (off-label use) (in combination with a multidose methotrexate regimen): IM: Methotrexate on days 1, 3, 5, and 7 alternating with leucovorin calcium 0.1 mg/kg on days 2, 4, 6, and 8. Measure serum hCG on each day of methotrexate administration. If serum hCG decreases by >15% from previous measurement, discontinue methotrexate and leucovorin (total treatment may be between 1 and 4 doses each). If serum hCG decreases by <15% from previous measurement, administer methotrexate (maximum 4 doses) and then leucovorin calcium the next day (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling. The risk for adverse reactions may be increased in patients with impaired kidney function.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Leucovorin: Pediatric drug information")

Note: Dosing in pediatric patients presented in mg, mg/m2 and mg/kg; use caution. Because oral absorption is saturable at doses >25 mg, administration of single oral doses >25 mg is not recommended (convert to parenteral therapy). Also consider parenteral administration instead of oral in patients with GI toxicity, nausea, vomiting, or who may be unreliable with the precisely timed administration (eg, infants and young children) needed for some indications.

Cerebral folate deficiency; treatment

Cerebral folate deficiency; treatment: Limited data available: Children and Adolescents: Oral: Initial: 0.5 to 1 mg/kg/day; titrate in 0.5 mg/kg/day increments at monthly intervals based on 5-methyltetrahydrofolate (5MTHF) levels in the cerebrospinal fluid (CSF); doses up to 2 to 3 mg/kg/day may be required. (Ref). Daily doses of 15 to 30 mg have been reported in adolescent patients (Ref).

Folic acid antagonist overdose

Folic acid antagonist (eg, pyrimethamine, trimethoprim) overdose: Infants, Children, and Adolescents: Oral: 5 to 15 mg daily.

Folinic-acid responsive seizures

Folinic-acid responsive seizures: Very limited data available: Infants and Children: Oral: Initial: 2.5 to 5 mg twice daily; may gradually increase for seizure recurrence; doses up to 8 mg/kg/day (eg, 25 mg 3 times daily) have been reported. Dosing based on small case series and case reports in patients with refractory seizures who were on multiple antiseizure medications with or without pyridoxine (Ref).

Megaloblastic anemia secondary to folate deficiency

Megaloblastic anemia secondary to folate deficiency: Infants, Children, and Adolescents: IM, IV: ≤1 mg/day; Note: Although an FDA-approved indication, folic acid is generally used to treat folate deficiency due to inadequate intake (eg, dietary, increased requirements) (Ref).

Methotrexate rescue, high-dose

Methotrexate rescue, high-dose: Note: Leucovorin calcium is a substrate for glucarpidase and may compete with methotrexate for binding sites; when administering glucarpidase concomitantly with leucovorin calcium, administer leucovorin calcium ≥2 hours before or 2 hours after the glucarpidase dose (Ref). Do not administer leucovorin intrathecally; the use of intrathecal leucovorin is not advised (Ref).

Infants, Children, and Adolescents: Dosing regimens variable, refer to specific protocols. Manufacturer labeling:

Initial: Oral, IM, IV: 15 mg (~10 mg/m2) every 6 hours; start 24 hours after beginning of methotrexate infusion (based on a methotrexate dose of 12 to 15 g/m2 IV over 4 hours). Leucovorin (and hydration and urinary alkalinization) should be continued and/or adjusted until the methotrexate level is <0.05 micromolar (5 x 10-8 M); the manufacturer labeling suggests 10 doses; although some patients may require more. Adjust dose as follows:

Normal methotrexate elimination (serum methotrexate level ~10 micromolar at 24 hours after administration, 1 micromolar at 48 hours, and <0.2 micromolar at 72 hours): Oral, IM, IV: 15 mg every 6 hours for 10 doses beginning 24 hours after the start of methotrexate infusion.

Delayed late methotrexate elimination (serum methotrexate level remaining >0.2 micromolar at 72 hours and >0.05 micromolar at 96 hours after administration): Oral, IM, IV: Continue leucovorin calcium 15 mg every 6 hours until methotrexate level is <0.05 micromolar.

Delayed early methotrexate elimination and/or acute renal injury (serum methotrexate level ≥50 micromolar at 24 hours, or ≥5 micromolar at 48 hours, or a doubling of serum creatinine level at 24 hours after methotrexate administration): IV: 150 mg every 3 hours until methotrexate level is <1 micromolar, then 15 mg every 3 hours until methotrexate level is <0.05 micromolar.

Methotrexate overexposure

Methotrexate overexposure (high dose): Limited data available: Note: Leucovorin calcium is a substrate for glucarpidase and may compete with methotrexate for binding sites; when administering glucarpidase concomitantly with leucovorin calcium, administer leucovorin calcium ≥2 hours before or 2 hours after the glucarpidase dose (Ref). Do not administer leucovorin intrathecally; the use of intrathecal leucovorin is not advised (Ref).

Infants, Children, and Adolescents: Leucovorin nomogram dosing for high-dose methotrexate overexposure (generalized dosing derived from reference nomogram figures, refer to each reference (Ref) or protocol-specific nomogram for details):

At 24 hours:

For methotrexate levels of ≥100 micromolar at ~24 hours, leucovorin is initially dosed at 1,000 mg/m2 IV every 6 hours.

For methotrexate levels of ≥10 to <100 micromolar at 24 hours, leucovorin is initially dosed at 100 mg/m2 IV every 3 or 6 hours.

For methotrexate levels of ~1 to 10 micromolar at 24 hours, leucovorin is initially dosed at 10 mg/m2 IV or orally every 3 or 6 hours.

At 48 hours:

For methotrexate levels of ≥100 micromolar at 48 hours, leucovorin is dosed at 1,000 mg/m2 IV every 6 hours.

For methotrexate levels of ≥10 to <100 micromolar at 48 hours, leucovorin is dosed at 100 mg/m2 IV every 3 hours.

For methotrexate levels of ~1 to 10 micromolar at 48 hours, leucovorin is dosed at 100 mg/m2 IV every 6 hours or 10 mg/m2 IV or orally to 100 mg/m2 IV every 3 hours.

At 72 hours:

For methotrexate levels of ≥10 micromolar at 72 hours, leucovorin is dosed at 100 to 1,000 mg/m2 IV every 3 to 6 hours

For methotrexate levels of ~1 to 10 micromolar at 72 hours, leucovorin is dosed at 10 mg/m2 IV or orally to 100 mg/m2 IV every 3 hours

For methotrexate levels of ~0.1 to 1 micromolar at 72 hours, leucovorin is dosed at 10 mg/m2 IV or orally every 3 to 6 hours

If serum creatinine is increased more than 50% above baseline, increase the standard leucovorin dose to 100 mg/m2 IV every 3 hours, then adjust according to methotrexate levels above.

Follow methotrexate levels daily, leucovorin may be discontinued when methotrexate level is <0.1 micromolar; some have suggested <0.08 micromolar (8 x 10-8 M) is preferable (Ref).

Methotrexate overdose

Methotrexate overdose (inadvertent): Note: For oncology patients, refer to protocol-specific nomograms for dosing. Manufacturer labeling:

Infants, Children, and Adolescents: Oral, IM, IV: 10 mg/m2/dose every 6 hours until the methotrexate level is <0.01 micromolar begin as soon as possible after overdose. If serum creatinine is increased more than 50% above baseline 24 hours after methotrexate administration, if 24-hour methotrexate level is >5 micromolar, or if 48-hour methotrexate level is >0.9 micromolar, increase leucovorin dose to 100 mg/m2 IV every 3 hours until the methotrexate level is <0.01 micromolar.

Note: Do not administer leucovorin intrathecally; use of intrathecal leucovorin is not advised (Ref).

Pyrimethamine hematologic toxicity, prevention

Pyrimethamine hematologic toxicity, prevention: Note: Leucovorin is administered in combination with pyrimethamine and other medications in the treatment of various infections (eg, toxoplasmosis, Pneumocystis jirovecii pneumonia (PCP), cystoisosporiasis); dosing varies with disease process and regimen; consult pyrimethamine specific monograph for additional details; duration of therapy varies based on disease state; however, leucovorin should typically continue for 1 week after pyrimethamine is discontinued (Ref); consultant specific guidelines; usual regimens include:

Toxoplasmosis (Toxoplasma gondii):

Treatment:

Congenital toxoplasmosis: Infants:

HIV-exposed/-infected: IM, Oral: 10 mg with every pyrimethamine dose; treatment duration: 12 months (Ref).

Non-HIV-exposed/-infected: IM, Oral: 10 mg 3 times weekly for 12 months (Ref).

Acquired infection:

HIV-exposed/-infected: Infants, Children, and Adolescents: Acute induction: Oral: 10 to 25 mg once daily for ≥6 weeks (Ref). Note: In adolescents, leucovorin may be increased to 50 to100 mg/day in divided doses (twice-daily doses) in cases of pyrimethamine toxicity (rash, nausea, bone marrow suppression) (Ref).

Non-HIV-exposed/-infected: Chorioretinitis: Infants, Children, and Adolescents: Oral: 10 to 20 mg three times weekly (Ref).

Prophylaxis:

Primary:

HIV-exposed/-infected:

Infants and Children: Oral: 5 mg once every 3 days (Ref).

Adolescents: Oral: 25 mg once weekly (with pyrimethamine and dapsone) or 10 mg once daily (with pyrimethamine and atovaquone) (Ref).

Hematopoietic stem cell transplantation recipients:

Children: Oral: 5 mg every 3 days; initiate after engraftment and administer as long as the patient remains on immunosuppressive therapy (Ref).

Adolescents: Oral: 10 to 25 mg once daily; initiate after engraftment and administer as long as the patient remains on immunosuppressive therapy (Ref).

Secondary (suppressive therapy): HIV-exposed/-infected:

Infants and Children: Oral: 5 mg once every 3 days (Ref).

Adolescents: Oral: 10 to 25 mg once daily (Ref).

Pneumocystis jirovecii pneumonia (PCP): Prophylaxis (primary and secondary): Adolescents: Oral: 25 mg once weekly (in combination with pyrimethamine and dapsone) or 10 mg once daily (in combination with pyrimethamine and atovaquone) (Ref).

Cystoisosporiasis (formerly isosporiasis), HIV-exposed/-infected:

Treatment, acute infection:

Infants and Children: Oral: 5 to 15 mg once daily in combination with pyrimethamine (Ref).

Adolescents: Oral: 10 to 25 mg once daily in combination with pyrimethamine (Ref).

Prophylaxis, secondary:

Infants and Children: Oral: 5 to 15 mg once daily (Ref).

Adolescents: Oral: 5 to 10 mg once daily (Ref).

Methanol toxicity; adjunctive cofactor therapy

Methanol toxicity; adjunctive cofactor therapy: Limited data available: Infants, Children, and Adolescents: IV: 1 mg/kg/dose (maximum dose: 50 mg/dose) over 30 to 60 minutes every 4 to 6 hours. Therapy should continue until methanol and formic acid have been completely eliminated (Ref). Note: Administration during methanol toxicity is especially important in patients who abuse ethanol as these patients may have chronic folate deficiency.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Infants, Children, and Adolescents: There are no dosage adjustments provided in manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

Infants, Children, and Adolescents: There are no dosage adjustments provided in manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported in combination with 5-fluorouracil.

>10%:

Central nervous system: Fatigue (≤13%), lethargy (≤13%), malaise (≤13%)

Dermatologic: Alopecia (42% to 43%), dermatitis (21% to 25%)

Gastrointestinal: Stomatitis (75% to 84%; grades ≥3: 27% to 29%), nausea (74% to 80%), diarrhea (66% to 67%), vomiting (44% to 46%), anorexia (14% to 22%)

Miscellaneous: Drug toxicity

1% to 10%:

Gastrointestinal: Constipation (3% to 4%)

Infection: Infection (3% to 8%)

Frequency not defined: Gastrointestinal: Gastrointestinal toxicity

Postmarketing: Anaphylactic shock, anaphylaxis, hypersensitivity reaction, nonimmune anaphylaxis, seizure, syncope, urticaria

Contraindications

Pernicious anemia and other megaloblastic anemias secondary to vitamin B12-deficiency.

Canadian labeling: Additional contraindications (not in the US labeling): Hypersensitivity to leucovorin or any component of the formulation; intrathecal administration.

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity: Hypersensitivity, including allergic reactions, anaphylactoid reactions, and urticaria have been reported with leucovorin. Because leucovorin is typically administered in combination with other chemotherapy agents, it may be difficult to determine the causative agent for hypersensitivity reactions. In a series of 44 patients with hypersensitivity to leucovorin-containing regimens, hypersensitivity/infusion reaction to leucovorin was confirmed in 5 patients; reactions also occurred with subsequent rechallenge with LEVOleucovorin (Ureña-Tavera 2015).

• Seizures: Seizures or syncope have been reported (rarely) in patients with cancer receiving leucovorin, usually in association with fluoropyrimidine administration, and most commonly in patients with CNS metastases or other predisposing factors; a causal relationship has not been established.

Disease-related concerns:

• Anemias: Leucovorin is inappropriate treatment for pernicious anemia and other megaloblastic anemias secondary to a lack of vitamin B12; a hematologic remission may occur while neurologic manifestations progress.

Concurrent drug therapy issues:

• Fluorouracil: Leucovorin may increase the toxicity of 5-fluorouracil; deaths from severe enterocolitis, diarrhea, and dehydration have been reported (in elderly patients); granulocytopenia and fever have also been reported.

• Sulfamethoxazole-trimethoprim: The combination of leucovorin and sulfamethoxazole-trimethoprim for the acute treatment of Pneumocystis jirovecii pneumonia in patients with HIV infection has been reported to cause increased rates of treatment failure.

Dosage form specific issues:

• Administration route: Parenteral administration may be preferred to oral if vomiting or malabsorption is likely. Because oral absorption is saturable at doses >25 mg, administering oral doses >25 mg is not recommended (convert to parenteral therapy).

• Benzyl alcohol and derivatives: When doses >10 mg/m2 are required using the powder for injection, reconstitute using sterile water for injection, not a solution containing benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.

Other warnings and precautions:

• Folic acid antagonist overdose: When used for the treatment of accidental folic acid antagonist overdose, administer as soon as possible.

• Methanol toxicity: Leucovorin is the reduced form of folic acid; leucovorin is rapidly converted to tetrahydrofolic acid derivatives, which are the storage forms of folate in the body. Because leucovorin does not require metabolic reduction, it is the preferred form of folate in the treatment of methanol toxicity. Administration during methanol toxicity is especially important in patients with chronic alcohol use disorder as these patients may have chronic folate deficiency. Clinicians should note that leucovorin is an adjunctive therapy and should never be used as the sole intervention in the management of methanol toxicity (AACT [Barceloux 2002]).

• Methotrexate overdose: When used for the treatment of a methotrexate overdose, administer IV leucovorin as soon as possible. Monitoring of the serum methotrexate concentration is essential to determine the optimal dose/duration of leucovorin; however, do not wait for the results of a methotrexate level before initiating leucovorin. It is important to adjust the leucovorin dose once a methotrexate level is known. The dose may need to be increased or administration prolonged in situations in which methotrexate excretion may be delayed (eg, ascites, pleural effusion, renal insufficiency, inadequate hydration). Never administer leucovorin intrathecally.

• Methotrexate rescue therapy: Methotrexate serum concentrations should be monitored to determine dose and duration of leucovorin therapy. Dose may need to be increased or administration prolonged in situations where methotrexate excretion may be delayed (eg, ascites, pleural effusion, renal insufficiency, inadequate hydration). Never administer leucovorin intrathecally.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Injection [strength expressed as base, preservative free]:

Generic: 100 mg/10 mL (10 mL); 500 mg/50 mL (50 mL)

Solution Reconstituted, Injection [strength expressed as base]:

Generic: 50 mg (1 ea); 100 mg (1 ea); 200 mg (1 ea); 500 mg (1 ea)

Solution Reconstituted, Injection [strength expressed as base, preservative free]:

Generic: 50 mg (1 ea); 100 mg (1 ea); 200 mg (1 ea); 350 mg (1 ea); 500 mg (1 ea)

Tablet, Oral [strength expressed as base]:

Generic: 5 mg, 10 mg, 15 mg, 25 mg

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Leucovorin Calcium Injection)

100 mg/10 mL (per mL): $2.89

500 mg/50 mL (per mL): $2.84

Solution (reconstituted) (Leucovorin Calcium Injection)

50 mg (per each): $12.00

100 mg (per each): $19.20 - $24.00

200 mg (per each): $12.00 - $48.00

350 mg (per each): $31.20 - $84.00

500 mg (per each): $103.43 - $120.00

Tablets (Leucovorin Calcium Oral)

5 mg (per each): $1.68 - $2.36

10 mg (per each): $8.41

15 mg (per each): $11.78

25 mg (per each): $11.18 - $24.73

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Injection:

Generic: 50 mg/5 mL (5 mL); 200 mg/20 mL (20 mL); 1000 mg/100 mL (100 mL)

Solution, Intravenous:

Generic: 10 mg/mL (5 mL, 30 mL, 50 mL)

Tablet, Oral [strength expressed as base]:

Generic: 5 mg, 15 mg

Administration: Adult

Due to calcium content, do not administer IV solutions at a rate >160 mg/minute; not intended for intrathecal use.

Refer to individual protocols. Should be administered IM, IV push, or IV infusion (15 minutes to 2 hours). Leucovorin should not be administered concurrently with methotrexate. It is commonly initiated 24 hours after the start of methotrexate. Leucovorin calcium is a substrate for glucarpidase and may compete with methotrexate for binding sites; when administering glucarpidase concomitantly with leucovorin calcium, administer leucovorin calcium at least 2 hours before or 2 hours after the glucarpidase dose (Ref).

As a rescue after folate antagonists: Administer by IV bolus, IM, or orally.

Do not administer orally in the presence of nausea or vomiting. Because oral absorption is saturable at doses >25 mg, administering oral doses >25 mg is not recommended (convert to parenteral therapy).

Combination therapy with fluorouracil: Fluorouracil is usually given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by IV bolus injection or short (10 to 120 minutes) IV infusion. Other administration schedules have been used; refer to individual protocols.

For the treatment of methanol toxicity, infuse over 30 to 60 minutes (Ref).

Administration: Pediatric

Oral: Do not administer orally in the presence of nausea or vomiting. Because oral absorption is saturable at doses above 25 mg, administering oral doses >25 mg is not recommended (convert to parenteral therapy).

Parenteral: Due to calcium content, do not administer IV solutions at a rate >160 mg/minute; not intended for intrathecal use.

Refer to individual protocols. Should be administered IM, IV push, or IV infusion (15 minutes to 2 hours). Leucovorin should not be administered concurrently with methotrexate. It is commonly initiated 24 hours after the start of methotrexate. Toxicity to normal tissues may be irreversible if leucovorin is not initiated by ~40 hours after the start of methotrexate.

As a rescue after folate antagonists: Administer by IV bolus, IM, or orally.

Combination therapy with fluorouracil: Fluorouracil is usually given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by IV bolus injection or short (10 to 120 minutes) IV infusion. Other administration schedules have been used; refer to individual protocols.

For the treatment of methanol toxicity, infuse over 30 to 60 minutes (Ref)

Use: Labeled Indications

Colorectal cancer, advanced: Injection: Palliative treatment of advanced colorectal cancer to prolong survival (in combination with fluorouracil).

Megaloblastic anemia: Injection: Treatment of megaloblastic anemias due to folic acid deficiency (when oral therapy is not feasible).

Methotrexate toxicity:

Injection: Rescue agent after high-dose methotrexate treatment in osteosarcoma and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.

Oral: Rescue agent to diminish toxicity and counteract effects of impaired methotrexate elimination and inadvertent overdoses of folic acid antagonists.

Use: Off-Label: Adult

Acute lymphocytic leukemia; Anal carcinoma, advanced; Biliary tract cancer, metastatic, progressive; Bladder cancer, neoadjuvant treatment; Dermatomyositis/polymyositis; Esophageal cancer, advanced or metastatic; Gastric cancer, advanced or metastatic; Gestational trophoblastic neoplasia, low risk; Gestational trophoblastic neoplasia, high risk; Graft-versus-host disease, acute, prophylaxis; Granulomatosis with polyangiitis and microscopic polyangiitis (maintenance therapy after remission induction); Methanol toxicity (adjunctive cofactor therapy); Non-Hodgkin lymphoma; Nonleukemic meningeal cancer; Pancreatic cancer, advanced or metastatic; Pancreatic cancer, potentially curable, adjuvant therapy; Prevention of pyrimethamine hematologic toxicity in patients with HIV; Primary CNS lymphoma, newly diagnosed; Small bowel adenocarcinoma, advanced or metastatic; Tubal ectopic pregnancy

Medication Safety Issues
Sound-alike/look-alike issues:

Leucovorin calcium may be confused with Leukeran, Leukine, LEVOleucovorin

Folinic acid may be confused with folic acid

Folinic acid is an error prone synonym and should not be used

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Fluorouracil Products: Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Fluorouracil Products. Risk C: Monitor therapy

Fosphenytoin: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Fosphenytoin. Risk C: Monitor therapy

Glucarpidase: May decrease serum concentrations of the active metabolite(s) of Leucovorin Calcium-Levoleucovorin. Specifically, 6S-5-methyltetrahydrofolateconcentrations may be reduced. Glucarpidase may decrease the serum concentration of Leucovorin Calcium-Levoleucovorin. Management: Avoid leucovorin administration within 2 hours of glucarpidase dosing. Continue to administer the pre-glucarpidase leucovorin dose for at least the first 48 hours after glucarpidase administration, and dose based on methotrexate concentration thereafter. Risk D: Consider therapy modification

PHENobarbital: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of PHENobarbital. Risk C: Monitor therapy

Phenytoin: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Phenytoin. Risk C: Monitor therapy

Primidone: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Primidone. Additionally, leucovorin/levoleucovorin may decrease concentrations of active metabolites of primidone (e.g., phenobarbital). Risk C: Monitor therapy

Raltitrexed: Leucovorin Calcium-Levoleucovorin may diminish the therapeutic effect of Raltitrexed. Risk X: Avoid combination

Trimethoprim: Leucovorin Calcium-Levoleucovorin may diminish the therapeutic effect of Trimethoprim. Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for Pneumocystis jirovecii pneumonia. If trimethoprim is used for another indication, monitor closely for reduced efficacy. Risk X: Avoid combination

Pregnancy Considerations

Animal reproduction studies have not been conducted. Leucovorin is a biologically active form of folic acid. Adequate amounts of folic acid are recommended during pregnancy. Refer to Folic Acid monograph.

Breastfeeding Considerations

Leucovorin is a biologically active form of folic acid. Adequate amounts of folic acid are recommended in breastfeeding patients. The manufacturer recommends caution be used if administered to a breastfeeding patient. Refer to Folic Acid monograph.

Dietary Considerations

Solutions for injection contain calcium 0.004 mEq per leucovorin 1 mg

Monitoring Parameters

High-dose methotrexate therapy: Plasma methotrexate concentration; leucovorin is continued until the plasma methotrexate level <0.05 micromolar or per institutional protocol. With 4- to 6-hour high-dose methotrexate infusions, plasma drug values in excess of 50 and 1 micromolar at 24 and 48 hours after starting the infusion, respectively, are often predictive of delayed methotrexate clearance. CBC with differential and platelets, LFTs, renal function tests.

Fluorouracil therapy: CBC with differential and platelets, liver function tests, electrolytes

Tubal ectopic pregnancy (in combination with mulitdose methotrexate) (off-label use): Prior to therapy, serial hCG measurements 2 to 7 days apart along with other procedures to exclude the presence of a viable intrauterine pregnancy (ACOG 193 2018; RCOG [Elson 2016]). CBC with differential, liver function tests, serum creatinine, blood type and Rh (ASRM 2013). Evaluate for medical conditions considered absolute contraindications for methotrexate treatment of ectopic pregnancy (ACOG 193 2018). Measure serum hCG on days of methotrexate administration. Once decrease is >15%, continue to measure serum hCG weekly until reaching a non-pregnant level. Consider surgical management if serum hCG does not decrease after 4 doses (ACOG 193 2018).

Mechanism of Action

Leucovorin calcium is a reduced form of folic acid, leucovorin supplies the necessary cofactor blocked by methotrexate. Leucovorin actively competes with methotrexate for transport sites, displaces methotrexate from intracellular binding sites, and restores active folate stores required for DNA/RNA synthesis. Leucovorin stabilizes the binding of 5-dUMP and thymidylate synthetase, enhancing the activity of fluorouracil. When administered with pyrimethamine for the treatment of opportunistic infections, leucovorin reduces the risk for hematologic toxicity (HHS [OI adult 2020]).

Methanol toxicity treatment: Formic acid (methanol’s toxic metabolite) is normally metabolized to carbon dioxide and water by 10-formyltetrahydrofolate dehydrogenase after being bound to tetrahydrofolate. Administering a source of tetrahydrofolate may aid the body in eliminating formic acid (AACT [Barceloux 2002]).

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Oral, IM: Well absorbed; oral absorption is saturable at doses >25 mg.

Metabolism: Intestinal mucosa and hepatically to 5-methyl-tetrahydrofolate (5MTHF; active)

Bioavailability: Saturable at oral doses >25 mg; 25 mg (97%), 50 mg (75%), 100 mg (37%)

Half-life elimination: ~4 to 8 hours

Time to peak: Oral: ~2 hours; IV: Total folates: 10 minutes; 5MTHF: ~1 hour; IM: Total folates: 52 minutes; 5MTHF: 2.8 hours

Excretion: Urine (primarily); feces

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Calcium leucovorin | Calciumfolinat | Chemonate;
  • (AR) Argentina: Asovorin | Elvefocal | Estroquin | Folinfabra | Leucocalcin | Leucovorina calcica teva | Leucovorina delta farma | Leucovorina filaxis | Leucovorina gp pharm | Leucovorina raffo | Leucovorina richet | Leucovorina servycal | Rontafor;
  • (AT) Austria: Calciumfolinat | Leucovorin;
  • (AU) Australia: Calcium leucovorin | Leucovorin calcium;
  • (BD) Bangladesh: Biofol | Folita;
  • (BE) Belgium: Rescuvolin;
  • (BR) Brazil: Calfolin | Folicorin | Folinac | Folinato de calcio | Leucovorina calcica | Levorin | Nyrin | Prevax | Rescuvolin | Tecnovorin;
  • (CH) Switzerland: Leucovorin;
  • (CL) Chile: Leucovorina;
  • (CN) China: Ai jie kang | Ai ru xi | Antrex | Ao luo ya | Bo sheng | Fu li neng | Fu neng | Gai er qing | Leucovorin calcium | Ou li | Rescuvolin | Shi ming | Tong ao;
  • (CO) Colombia: Alonat | Dalisol | Folical | Folinato de calcio | Leucovorin calcium | Leucovorina | Lucal | Rescuvolin | Tecnovorin;
  • (CZ) Czech Republic: Leucovorin | Leucovorin calcium;
  • (DE) Germany: Calciumfolinat | Calciumfolinat gry | Lederfolat | Leucovorin | Rescuvolin | Zytofolin;
  • (DK) Denmark: Calciumfolinat mayne;
  • (DO) Dominican Republic: Leucovorin | Leucovorina Calcico;
  • (EC) Ecuador: Leucovorina | Leucovorina kemex | Tecnovorin;
  • (EE) Estonia: Antrex | Leucovorin | Neovorin;
  • (EG) Egypt: Nyrin;
  • (ES) Spain: Cromatonbic folinico | Folidan | Folinato calcico G.E.S | Folinato calcico Normon | Lederfolin;
  • (FI) Finland: Antrex | Leucovorin | Rescuvolin;
  • (FR) France: Folinate de calcium aguettant | Folinate de calcium altan | Folinate de calcium dakota pharm | Folinate de calcium zentiva | Lederfoline | Perfolate;
  • (GB) United Kingdom: Calc leucovorn | Calcium folint | Calcium leucovorn | Folic acid roche | Lederfolin | Refolinon;
  • (GR) Greece: Calcifolin | Calcium leucovorin | Claro | Fedolen | Folical | Folinacid | Folinato | Foxolin | Leucovorin | Reotan | Rescuvolin | Vivalcid;
  • (HK) Hong Kong: Leucovorin | Leucovorin calcium | Rescuvolin;
  • (HU) Hungary: Lederfoline | Leucovorin ca | Leucovorin teva;
  • (ID) Indonesia: Erbanfol | Leucovorin calcium | Rescuvolin;
  • (IE) Ireland: Folinic acid | Leucovorin;
  • (IL) Israel: Leucovorin | Rescuvolin;
  • (IN) India: Adcov | Biovorin | Fastovorin | Leucorin | Leucovorin | Leucovorin calcium | Leutero | Neovorin | Nyrin | Recovorin | Unifolin | Zovorin;
  • (IT) Italy: Calcio Folinato | Calcium Folinato | Calfolex | Calinat | Citofolin | Divifolin | Ecofol | Folaren | Foliben | Folidar | Folinvit | Foliplus | Lederfolin | Resfolin | Sanifolin | Sulton | Tonofolin;
  • (JO) Jordan: Leucovorin calcium;
  • (JP) Japan: Calcium folinate nk | Folinate dsep | Folinate jg | Folinate ohara | Folinate sawai | Folinate towa | Uzel;
  • (KR) Korea, Republic of: Ferbon | Leucovorin | Nyrin | Rescuvolin | Robin;
  • (LB) Lebanon: Leucovorin calcium;
  • (LT) Lithuania: Antrex | Calcifolin | Calciumfolinat | Lederfolat | Leucovorin calcium;
  • (LU) Luxembourg: Ledervorin | Rescuvolin;
  • (LV) Latvia: Antrex | Lederfolat | Leucovorin;
  • (MX) Mexico: Acido folinico | Dalisol | Ifavor | Leucovorin | Medsavorina;
  • (MY) Malaysia: Folina | Leucovorin | Leucovorin calcium | Rescuvolin;
  • (NL) Netherlands: Calciumfolinaat Ebewe | Leucovorine | Rescuvolin;
  • (NO) Norway: Calcio folinato sandoz | Calciumfolinate teva | Kalsiumfolinat | Leucovorin | Rescuvolin;
  • (NZ) New Zealand: Leucovorin | Leucovorin calcium;
  • (PE) Peru: Etamolin | Folinato calcico | Folinato de calcio | Leucovorina | Tecnovorin;
  • (PH) Philippines: Rescuvolin;
  • (PK) Pakistan: Leucovorin | Rescuvolin;
  • (PL) Poland: Antrex | Biovorin | Calcium folinate actavis | Calcium folinate hospira | Lederfolat | Leucovorin | Leucovorin ca | Rescuvolin;
  • (PR) Puerto Rico: Leucovorin | Leucovorin calcium;
  • (PT) Portugal: Folinato Calcico Teva | Lederfoline;
  • (PY) Paraguay: Estroquin | Leucocalcin | Leucovorin libra | Leucovorina calcica fapasa | Leucovorina fapasa | Leucovorina fusa | Novizet | Rontafor;
  • (QA) Qatar: Folca | Refolinon;
  • (RO) Romania: Folcasin;
  • (RU) Russian Federation: Calcium folinate vial | Dalisol | Leikovorin lahema | Leucovorin | Leucovorin Lachema | Leucovorin lens | Leucovorine lans;
  • (SA) Saudi Arabia: Calcium leucovorin;
  • (SE) Sweden: Calciumfolinate teva | Leucovorin;
  • (SG) Singapore: Leucovorin | Leucovorin calcium | Rescuvolin;
  • (SI) Slovenia: Leucovorin;
  • (SK) Slovakia: Leucovorin | Leucovorin ca;
  • (TH) Thailand: Calciumfolinat ebewe | Folina | Leucovorin calcium | Leucovorin dabur | Leukovorin | Nyrin | Rescuvolin;
  • (TN) Tunisia: Folinate calcium | Folinate de calcium aguettant | Lederfoline | Protektor;
  • (TR) Turkey: Antrex | Calciumfolinat ebewe | Folca | Leucovorin teva | Rescuvolin;
  • (TW) Taiwan: Antrex | Bloodlet | Cafonia | Calciumfolinat | Calife | Folina | Leucovorin | Leucovorin calcium | Rescuvolin;
  • (UA) Ukraine: Leucovorin | Leucovorin amaxa | Leucovorin calcium | Leucovorin lens;
  • (UY) Uruguay: Folinato de calcio | Leucovorin | Leucovorina | Rontafor;
  • (VE) Venezuela, Bolivarian Republic of: Leuconolver;
  • (ZA) South Africa: Abic leucovorin | Folinic acid | Leucovorin | Leucovorin faulding | Rescuvolin;
  • (ZM) Zambia: Unifolin;
  • (ZW) Zimbabwe: Rescuvolin
  1. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  2. Al-Baradie RS, Chaudhary MW. Diagnosis and management of cerebral folate deficiency. A form of folinic acid-responsive seizures. Neurosciences (Riyadh). 2014;19(4):312‐316. [PubMed 25274592]
  3. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435-1442. [PubMed 18349393]
  4. Al-Batran SE, Homann N, Pauligk C, et al; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. [PubMed 30982686]
  5. Alberts SR, Al-Khatib H, Mahoney MR, et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer. 2005;103(1):111-118. doi:10.1002/cncr.20753 [PubMed 15558814]
  6. American College of Obstetricians and Gynecologists ACOG Practice Bulletin No. 193: tubal ectopic pregnancy. Obstet Gynecol. 2018;131(3):e91-e103. doi: 10.1097/AOG.0000000000002560. [PubMed 29470343]
  7. André T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer. 1999;35(9):1343-1347. doi: 10.1016/s0959-8049(99)00150-1. [PubMed 10658525]
  8. Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(22):2654-2668. doi: 10.1200/JCO.2016.67.5561. [PubMed 27247216]
  9. Barceloux DG, Bond GR, Krenzelok EP, et al. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. J Toxicol Clin Toxicol. 2002;40(4):415-446. [PubMed 12216995]
  10. Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a meta-analysis comparing "single dose" and "multidose" regimens. Obstet Gynecol. 2003;101(4):778-784. [PubMed 12681886]
  11. Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21(6):1044-1049. doi:10.1200/JCO.2003.03.036. [PubMed 12637469]
  12. Bleyer WA. New Vistas for Leucovorin in Cancer Chemotherapy. Cancer. 1989;63(6)(suppl):995-1007. doi: 10.1002/1097-0142(19890315)63:6+<995::aid-cncr2820631302>3.0.co;2-r [PubMed 2645044]
  13. Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer. 1978;41(1):36-51. doi: 10.1002/1097-0142(197801)41:1<36::aid-cncr2820410108>3.0.co;2-i. [PubMed 342086]
  14. Bleyer WA. Therapeutic monitoring of methotrexate and other antineoplastic drugs. In Baer DM, Devits WR meds. Interpretations in Therapeutic Drug Monitoring. Chicago, IL: American Society of Clinical Pathology; 1981:169-181.
  15. Bradley JS and Nelson JD, eds. Nelson's Pediatric Antimicrobial Therapy. 25th ed. Itasca, IL: American Academy of Pediatrics; 2019.
  16. Briemberg HR, Amato AA. Dermatomyositis and polymyositis. Curr Treat Options Neurol. 2003;5(5):349-356. doi: 10.1007/s11940-003-0025-9. [PubMed 12895397]
  17. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  18. Cheeseman SL, Joel SP, Chester JD, et al. A ‘Modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer. 2002;87(4):393-399. doi: 10.1038/sj.bjc.6600467. [PubMed 12177775]
  19. Cloherty JP, Eichenwald EC, Stark AR, eds. Manual of Neonatal Care. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012.
  20. Conroy T, Desseigne F, Ychou M, et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825. doi: 10.1056/NEJMoa1011923. [PubMed 21561347]
  21. Conroy T, Hammel P, Hebbar M, et al; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395-2406. doi: 10.1056/NEJMoa1809775. [PubMed 30575490]
  22. Conroy T, Paillot B, François E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol. 2005;23(6):1228-1236. doi: 10.1200/JCO.2005.06.050 [PubMed 15718320]
  23. Conroy T, Yataghène Y, Etienne PL, et al. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer. 2010;103(9):1349-1355. doi:10.1038/sj.bjc.6605943 [PubMed 20940718]
  24. Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021 [PubMed 28669553]
  25. Devalia V, Hamilton MS, Molloy AM; British Committee for Standards in Haematology. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol. 2014;166(4):496‐513. [PubMed 24942828]
  26. Djukic A. Folate-responsive neurologic diseases. Pediatr Neurol. 2007;37(6):387-397. [PubMed 18021918]
  27. Eichenwald EC, ed. Cloherty and Stark's Manual of Neonatal Care. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2017.
  28. Eiriksson L, Dean E, Sebastianelli A, et al. Guideline no. 408: management of gestational trophoblastic diseases. J Obstet Gynaecol Can. 2021;43(1):91-105.e1. doi:10.1016/j.jogc.2020.03.001 [PubMed 33384141]
  29. Elson CJ, Salim R, Potdar N, Chetty M, Ross JA, Kirk EJ on behalf of the Royal College of Obstetricians and Gynaecologists (RCOG). Diagnosis and management of ectopic pregnancy: Green-top Guideline No. 21. BJOG. 2016;123(13):e15-e55. doi: 10.1111/1471-0528.14189. [PubMed 27813249]
  30. Enzinger PC, Burtness BA, Niedzwiecki D, et al. CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. J Clin Oncol. 2016;34(23):2736-2742. doi:10.1200/JCO.2015.65.5092 [PubMed 27382098]
  31. Escobar PF, Lurain JR, Singh DK, Bozorgi K, Fishman DA. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Gynecol Oncol. 2003;91(3):552-557. doi: 10.1016/j.ygyno.2003.08.028. [PubMed 14675675]
  32. Frye RE, Donner E, Golja A, Rooney CM. Folinic acid-responsive seizures presenting as breakthrough seizures in a 3-month-old boy. J Child Neurol. 2003;18(8):562-569. doi: 10.1177/08830738030180081001. [PubMed 13677584]
  33. Gallagher RC, Van Hove JL, Scharer G, et al. Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. Ann Neurol. 2009;65(5):550-556. doi: 10.1002/ana.21568. [PubMed 19142996]
  34. Ghaemmaghami F, Modares M, Arab M, et al. EMA-EP regimen, as firstline multiple agent chemotherapy in high-risk GTT patients (stage II-IV). Int J Gynecol Cancer. 2004;14(2):360-365. doi: 10.1111/j.1048-891X.2004.014222.x. [PubMed 15086738]
  35. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5(11):3394-3402. [PubMed 10589750]
  36. Glass J, Won M, Schultz CJ, et al. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227. J Clin Oncol. 2016;34(14):1620-1625. doi: 10.1200/JCO.2015.64.8634. [PubMed 27022122]
  37. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK; International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171-2177. [PubMed 21502557]
  38. Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014;32(31):3520-3526. [PubMed 25287828]
  39. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005;23(34):8671-8678. doi: 10.1200/JCO.2004.00.5686. [PubMed 16314627]
  40. Hansen FJ, Blau N. Cerebral folate deficiency: life-changing supplementation with folinic acid. Mol Genet Metab. 2005;84(4):371‐373. [PubMed 15781200]
  41. Hochster HS, Grothey A, Hart L, et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Ann Oncol. 2014;25(6):1172-1178. doi:10.1093/annonc/mdu107 [PubMed 24608198]
  42. Hyland K, Buist NR, Powell BR, et al. Folinic acid responsive seizures: a new syndrome?. J Inherit Metab Dis. 1995;18(2):177‐181. [PubMed 7564240]
  43. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  44. Jacobsen D, McMartin KE. Methanol and ethylene glycol poisonings. Mechanism of toxicity, clinical course, diagnosis and treatment. Med Toxicol. 1986;1(5):309-334. doi: 10.1007/bf03259846. [PubMed 3537623]
  45. Janjigian YY, Ajani JA, Moehler M, et al. First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial. J Clin Oncol. Published online February 21, 2024. doi:10.1200/JCO.23.01601 [PubMed 38382001]
  46. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27-40. doi:10.1016/S0140-6736(21)00797-2 [PubMed 34102137]
  47. Jardine LF, Ingram LC, Bleyer WA. Intrathecal leucovorin after intrathecal methotrexate overdose. J Pediatr Hematol Oncol. 1996;18(3):302-304. doi:10.1097/00043426-199608000-00014 [PubMed 8689347]
  48. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788-2801. doi: 10.1002/cncr.20668. [PubMed 15481055]
  49. Khorana AA, McKernin SE, Berlin J, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. J Clin Oncol. 2019;37(23):2082-2088. doi: 10.1200/JCO.19.00946. [PubMed 31180816]
  50. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998;16(12):3803-3809. doi: 10.1200/JCO.1998.16.12.3803. [PubMed 9850025]
  51. Kliegman RM and St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.
  52. Lacasce A, Howard O, Lib S, et al. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004;45(4):761-767. doi:10.1080/1042819031000141301 [PubMed 15160953]
  53. Lam MS. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. Pharmacotherapy. 2011;31(2):164-192. [PubMed 21275495]
  54. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med. 2003;114(6):463-469. doi: 10.1016/s0002-9343(03)00077-9. [PubMed 12727579]
  55. Lederle Leucovorin (calcium folinate) tablets, USP [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; October 2022.
  56. Leucovorin calcium for injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; April 2018.
  57. Leucovorin calcium for injection [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc: October 2021.
  58. Leucovorin calcium injection [product monograph]. Toronto, Ontario, Canada: Generic Medical Partners Inc; March 2020.
  59. Leucovorin calcium tablets [prescribing information]. Laurelton, NY: Epic Pharma, LLC; August 2019.
  60. Leucovorin calcium tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; May 2016.
  61. Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20(10):2464-2471. doi:10.1200/JCO.2002.07.116 [PubMed 12011123]
  62. Linker CA, Levitt LJ, O'Donnell M, Forman SJ, Ries CA. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood. 1991;78(11):2814-2822. [PubMed 1835410]
  63. Lurain JR, Singh DK, Schink JC. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. J Reprod Med. 2006;51(10):767-772. [PubMed 17086804]
  64. Machover D. A Comprehensive Review of 5-Fluorouracil and Leucovorin in Patients With Metastatic Colorectal Carcinoma. Cancer. 1997;80(7):1179-1187. [PubMed 9317168]
  65. Maindrault-Goebel F, Louvet C, André T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer. 1999;35(9):1338-1342. doi: 10.1016/s0959-8049(99)00149-5. [PubMed 10658524]
  66. McAuley JB. Toxoplasmosis in children. Pediatr Infect Dis J. 2008;27(2):161-162. [PubMed 18227714]
  67. McGuire BW, Sia LL, Leese PT, et al, “Pharmacokinetics of Leucovorin Calcium After Intravenous, Intramuscular, and Oral Administration,” Clin Pharm, 1988, 7(1):52-8. [PubMed 3257913]
  68. Mead GM, Barrans SL, Qian W, et al; UK National Cancer Research Institute Lymphoma Clinical Studies Group; Australasian Leukaemia and Lymphoma Group. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008;112(6):2248-2260. doi:10.1182/blood-2008-03-145128. [PubMed 18612102]
  69. Miller ML. Initial treatment of dermatomyositis and polymyositis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 24, 2022.
  70. Mondaca S, Chatila WK, Bates D, et al. FOLFCIS treatment and genomic correlates of response in advanced anal squamous cell cancer. Clin Colorectal Cancer. 2019;18(1):e39-e52. doi:10.1016/j.clcc.2018.09.005 [PubMed 30316684]
  71. Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971-3979. doi:10.1200/JCO.2013.50.4910 [PubMed 24101038]
  72. Nelson WE, Behrman RE, Kliegman RM, et al, eds. Nelson Textbook of Pediatrics. 15th ed. Philadelphia, PA: WB Saunders Company; 1996.
  73. Newlands ES, Mulholland PJ, Holden L, Seckl MJ, Rustin GJ. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol. 2000;18(4):854-859. doi: 10.1200/JCO.2000.18.4.854. [PubMed 10673528]
  74. Nicolai J, van Kranen-Mastenbroek VH, Wevers RA, Hurkx WA, Vles JS. Folinic acid-responsive seizures initially responsive to pyridoxine. Pediatr Neurol. 2006;34(2):164-167. [PubMed 16458834]
  75. Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32(23):2423-2429. doi: 10.1200/JCO.2013.53.6995 [PubMed 24982456]
  76. Oki Y, Westin JR, Vega F, et al. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013;163(5):611-620. doi:10.1111/bjh.12585 [PubMed 24117234]
  77. Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403-1410. doi:10.1182/blood-2014-10-604561 [PubMed 25568347]
  78. Ory SJ, Villanueva AL, Sand PK, Tamura RK. Conservative treatment of ectopic pregnancy with methotrexate. Am J Obstet Gynecol. 1986;154(6):1299-1306. [PubMed 2940870]
  79. Pagnoux C, Mahr A, Hamidou MA, et al; French Vasculitis Study Group. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790-2803. doi: 10.1056/NEJMoa0802311. [PubMed 19109574]
  80. Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47(11):1676-1681. doi: 10.1016/j.ejca.2011.04.011 [PubMed 21565490]
  81. Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7(2):e157-e167. doi:10.1016/S2352-3026(19)30256-X [PubMed 32004485]
  82. Practice Committee of American Society for Reproductive Medicine (ASRM). Medical treatment of ectopic pregnancy: a committee opinion. Fertil Steril. 2013;100(3):638-644. doi: 10.1016/j.fertnstert.2013.06.013. [PubMed 23849842]
  83. Ramaekers VT, Blau N. Cerebral folate deficiency. Dev Med Child Neurol. 2004;46(12):843‐851. [PubMed 15581159]
  84. Ramaekers VT, Häusler M, Opladen T, Heimann G, Blau N. Psychomotor retardation, spastic paraplegia, cerebellar ataxia and dyskinesia associated with low 5-methyltetrahydrofolate in cerebrospinal fluid: a novel neurometabolic condition responding to folinic acid substitution. Neuropediatrics. 2002;33(6):301‐308. [PubMed 12571785]
  85. Ramsey LB, Balis FM, O’Brien MM, et al. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist. 2018.23(1):52-61. doi: 10.1634/theoncologist.2017-0243 [PubMed 29079637]
  86. Refer to manufacturer’s labeling.
  87. Rowe JM, Buck G, Burnett AK, et al; ECOG; MRC/NCRI Adult Leukemia Working Party. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760-3767. doi:10.1182/blood-2005-04-1623 [PubMed 16105981]
  88. Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31(25):3061-3068. doi: 10.1200/JCO.2012.46.9957. [PubMed 23569323]
  89. Rustum YM. Modulation of Fluoropyrimidines by Leucovorin: Rationale and Status. J Surg Oncol Suppl. 1991;2:116-123. [PubMed 1832538]
  90. Sauer MV, Gorrill MJ, Rodi IA, et al. Nonsurgical management of unruptured ectopic pregnancy: an extended clinical trial. Fertil Steril. 1987;48(5):752-725. [PubMed 2444463]
  91. Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25(30):4730-4735. doi: 10.1200/JCO.2007.12.5062. [PubMed 17947720]
  92. Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. J Clin Oncol. 2015;33(33):3874-3879. doi:10.1200/JCO.2015.60.7465 [PubMed 26438119]
  93. Shah MA, Kennedy EB, Catenacci DV, et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. J Clin Oncol. 2020;38(23):2677-2694. doi:10.1200/JCO.20.00866 [PubMed 32568633]
  94. Smith SW, Nelson LS. Case files of the New York City Poison Control Center: antidotal strategies for the management of methotrexate toxicity. J Med Toxicol. 2008;4(2):132-140. doi:10.1007/BF03160968 [PubMed 18570175]
  95. Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. Published online August 5, 2020. doi:10.1200/JCO.20.01364 [PubMed 32755482]
  96. Stovall TG, Ling FW, Buster JE. Outpatient chemotherapy of unruptured ectopic pregnancy. Fertil Steril. 1989;51(3):435-438. [PubMed 2784113]
  97. Stovall TG, Ling FW, Gray LA. Single-dose methotrexate for treatment of ectopic pregnancy. Obstet Gynecol. 1991;77(5):754-757. [PubMed 2014091]
  98. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103(12):4396-4407. doi: 10.1182/blood-2003-08-2958. [PubMed 14551133]
  99. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106(7):1569-1580. doi: 10.1002/cncr.21776. [PubMed 16502413]
  100. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143-1238. [PubMed 19747629]
  101. Torres OA, Miller VS, Buist NM, Hyland K. Folinic acid-responsive neonatal seizures. J Child Neurol. 1999;14(8):529-532. [PubMed 10456764]
  102. Trissel LA, Martinez JF, Xu QA. Incompatibility of fluorouracil with leucovorin calcium or levoleucovorin calcium. Am J Health Syst Pharm. 1995;52(7):710-715. [PubMed 7627739]
  103. Ureña-Tavera A, Zamora-Verduga M, Madrigal-Burgaleta R, Angel-Pereira D, Berges-Gimeno MP, Alvarez-Cuesta E. Hypersensitivity reactions to racemic calcium folinate (leucovorin) during FOLFOX and FOLFIRI chemotherapy administrations. J Allergy Clin Immunol. 2015;135(4):1066-1067. [PubMed 25457996]
  104. US Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf. Updated December 2019. Accessed June 2, 2020.
  105. US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-arv/guidelines-pediatric-arv.pdf. Updated April 2020. Accessed June 2, 2020.
  106. US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf. Accessed May 4, 2020.
  107. Van Delden C, Hirschel B. Folinic acid supplements to pyrimethamine-sulfadiazine for Toxoplasma encephalitis are associated with better outcome. J Infect Dis, 1996, 173(5):1294-1295. [PubMed 8627092]
  108. Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272-1281. doi:10.1016/S0140-6736(23)01366-1 [PubMed 37708904]
  109. Walker SE, Law S, Puodziunas A. Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers. Can J Hosp Pharm. 2005;58(4):212-222.
  110. Wang-Gillam A, Li CP, Bodoky G, et al; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545-557. doi:10.1016/S0140-6736(15)00986-1 [PubMed 26615328]
  111. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694-703. [PubMed 16794248]
  112. Xiang XJ, Liu YW, Zhang L, et al. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anticancer Drugs. 2012;23(5):561-566. doi:10.1097/CAD.0b013e328350dd0d [PubMed 22481063]
  113. Yoo C, Kim KP, Jeong JH, et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol. 2021;22(11):1560-1572. doi:10.1016/S1470-2045(21)00486-1 [PubMed 34656226]
  114. Zaanan A, Costes L, Gauthier M, et al. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol. 2010;21(9):1786-1793. doi:10.1093/annonc/mdq038 [PubMed 20223786]
  115. Zaanan A, Gauthier M, Malka D, et al. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. Cancer. 2011;117(7):1422-1428. [PubMed 21425142]
Topic 9548 Version 367.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟